quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 23, 2025

Stock market today: S&P 500 notches latest 2025 record as Wall Street's winning streak reaches 4

View original at finance.yahoo.com
Stock market today: S&P 500 notches latest 2025 record as Wall Street's winning streak reaches 4 US stocks tipped higher on Tuesday, with the S&P 500 clinching a fresh record, as Wall Street shrugged off fresh data that showed surprisingly strong growth in the US economy over the summer that led investors to trim bets…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We'll have a cloud of wearables that'll be tuned to whatever your use case is

    80% confidence
  • The US dollar is on track to hit its weakest annual performance since 2017 according to the Bloomberg Dollar Index

    80% confidence
  • In the agentic AI era, intelligent trust and governance that span any cloud, any asset, any AI system, and any device are non-negotiable if companies want to scale AI for the long-term

    80% confidence
  • OpenAI device is just another form factor for computing

    80% confidence
  • We look forward to supporting the Navy on this critical program

    80% confidence
  • iPhone won't go away, just as the iPhone didn't fully replace laptops or desktops

    80% confidence
  • Together with Armis, we will deliver an industry-defining strategic cybersecurity shield for real-time, end-to-end proactive protection across all technology estates

    80% confidence
  • Consumer confidence declining for a fifth consecutive month, dropping 3.8 points to 89.1 in December from November's upwardly revised reading of 92.9

    80% confidence
  • US economy grew at a 4.3% annualized rate in third quarter, much higher than the 3.3% expected

    80% confidence
  • Alexa devices are fascinating but also kind of latent in the sort of bandwidth for information

    80% confidence
  • Sees room to revise the Federal Reserve's 2% inflation target and move to a range-based system instead

    80% confidence
  • OpenAI's device won't make the iPhone obsolete and would have a long way to go to drive mass appeal

    80% confidence
  • Consumers' views on current business conditions were negative for the first time since September 2024

    80% confidence
  • Consumer spending remained strong over the summer

    80% confidence
  • Survey respondents cited ongoing concerns such as inflation, tariffs, and politics

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · absolute change3.52 USD
Novo Nordisk A/S · daily change7.32 percent
Dow Jones Industrial Average · absolute change79.73 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Stock market today: S&P 500 notches latest 2025 record as Wall Street's winning streak reaches 4 — Source | Via News | pt.VIA.NEWS